BioXtek: Creating cutting-edge regenerative therapeutics from human birth tissue

BioXtek is revolutionizing healthcare by turning once discarded birth byproducts into powerful regenerative therapies that redefine patient care.

At birth, the baby is the headline event while the rest of the materials, which have played a crucial role in the intricate process of building a fully-functioning human from just two cells, are often discarded as medical waste. But what if these so-called “byproducts” held the key to groundbreaking medical treatments? Enter BioXtek™, a trailblazing biotech specializing in regenerative therapeutics derived from human birth tissues.

BioXtek envisions a future where medical therapeutics, carefully created from human placental tissues and their components, are processed into pharmaceutical-grade therapies. These therapies aim to regenerate sick or injured tissues at the cellular level, offering a revolutionary approach to healing that brings regenerative therapeutics into mainstream medicine, and that focuses on eradicating diseases, not just managing symptoms.

The company focuses on studying amniotic fluid and Wharton’s jelly, exploring both cellular and acellular functionalities across a wide range of pathologies. BioXtek’s innovative manufacturing platform aims to deliver consistent, potent and stable exosomes at scale, forming a diversified therapeutic platform that addresses unmet needs in wound care, musculoskeletal issues and human organ pathologies.

My take on this: BioXtek’s mission is to revolutionize allopathic medical treatments by introducing a new biologic paradigm focused on achieving superior patient outcomes without side effects or adverse events. Derived from qualified placental donors and using advanced cryopreservation and freeze-drying technologies, BioXtek’s products concentrate biologically active components such as exosomes, growth factors, peptides, cytokines, miRNA and mesenchymal stem cells. BioXtek solutions address key aspects of longevity and antiaging by promoting cellular regeneration, reducing inflammation and preventing fibrosis.

We sat down with Dr Bruce Werber, CEO of BioXtek to find out more about the incredible regenerative potential of placental derived tissues and the company’s drive to use this power to turn traditional subscription medicine upside down by resolving diseases rather than endlessly treating them.

BioXtek’s platform is built around the BIOPUR process – Preserving Bioactive Properties in Placental Tissues. Designed to ensure the preservation of the bioactive properties of placental tissues, it particularly focuses on the components like Wharton’s Jelly and amniotic fluid.

Following consent and a rigorous donor screening that scrutinizes medical history and ensures absence of transmissible diseases including COVID-19, the tissues are collected in a sterile environment immediately after delivery; C-section deliveries are preferred to minimize contamination, and cellular components are then removed with structural proteins and extracellular matrices intact and exosomes and other nanoparticles preserved.

“We ensure the structural proteins like collagen and glycosaminoglycans are preserved to maintain the ECM’s integrity, and maintain high levels of growth factors such as EGF, PDGF, and cytokines to enhance the regenerative properties of the tissue. It is also vital to preserve the exosomes and microRNAs that play critical roles in intercellular communication and tissue repair,” explains Werber, adding that the team is careful to maintain low temperatures during collection and initial processing to preserve the integrity of the bioactive molecules.

Explore how BioXtek is pioneering cutting-edge regenerative therapies from human birth tissue, its innovative products that ensure optimal healing and functional recovery, and more insights, straight from Dr Bruce Werber, DPM, MSc, FACFAS right HERE.

Thanks for reading! If you’ve enjoyed this article, it would mean a lot to me if you could subscribe and share it on LinkedIn!